Search Results
10
Everything
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025 09:08 ET
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025 16:45 ET
|
Alumis Inc.
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025 16:15 ET
|
Alumis Inc.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis Strengthens Leadership Team with Key Appointments
January 28, 2025 08:00 ET
|
Alumis Inc.
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024 08:00 ET
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 03, 2024 16:10 ET
|
Amarna Therapeutics
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development Leiden, The Netherlands, 3 December 2024 - Amarna Therapeutics, (“Amarna” or “the Company”), a...
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
November 04, 2024 08:00 ET
|
Alumis Inc.
Alumis CEO will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tues Nov 12 at 2:00 pm ET
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
September 27, 2024 09:00 ET
|
Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024 16:29 ET
|
Alumis Inc.
Alumis will be participating in several investor conferences in September
Alumis Announces Pricing of Initial Public Offering
June 27, 2024 23:57 ET
|
Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering